SCHEMBL2900702

SCHEMBL2900702

CCOC(=O)c1cnc(-c2cccs2)[nH]c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.57
ALDH1A1 P00352 6/20 0.57
L3MBTL1 Q9Y468 2/20 0.55
GAA P10253 4/20 0.49
KMT2A Q03164 2/20 0.49
FOS P01100 2/20 0.48
JUN P05412 2/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
GLA P06280 1/20 0.48
RECQL P46063 1/20 0.48
ERCC1 P07992 1/20 0.48
FEN1 P39748 1/20 0.48
ERCC4 Q92889 1/20 0.48
TDP1 Q9NUW8 2/20 0.47
MAPT P10636 2/20 0.46
POLB P06746 2/20 0.46
HPGD P15428 1/20 0.46
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11630436 0.81 KDM4E (0.55) KDM4EALDH1A1L3MBTL1GAAKMT2A
SCHEMBL2897245 0.80 KDM4E (0.72) KDM4EALDH1A1L3MBTL1GAANFKB1
SCHEMBL11632796 0.79 KDM4E (0.53) KDM4EALDH1A1L3MBTL1GAAKMT2A
SCHEMBL4763787 0.79 KDM4E (0.64) KDM4EALDH1A1L3MBTL1GAAFOS
SCHEMBL11626689 0.76 KDM4E (0.57) KDM4EALDH1A1L3MBTL1GAAKMT2A
SCHEMBL11631532 0.76 KDM4E (0.57) KDM4EALDH1A1L3MBTL1GAAKMT2A
SCHEMBL11628793 0.76 KDM4E (0.57) KDM4EALDH1A1L3MBTL1GAATDP1
SCHEMBL11632948 0.76 KDM4E (0.57) KDM4EALDH1A1L3MBTL1GAAKMT2A
SCHEMBL4949585 0.75 KDM4E (0.63) KDM4EALDH1A1L3MBTL1GAAFOS
SCHEMBL4376727 0.75 KDM4E (0.76) KDM4EALDH1A1L3MBTL1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT KDM4E 1257/4885ALDH1A1 897/4885L3MBTL1 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.